Capital Rx has filed a notice of an exempt offering of securities to raise $312,497,075.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Capital Rx is raising up to $312,497,075.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Anthony Loiacono played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Capital Rx
Capital Rx is a healthcare technology company changing the way prescription drugs are priced, and patients are cared for in America. As a Certified B Corp, Capital Rx is executing its mission through a Single Ledger Model, the industrys first ethical framework for drug pricing. The companys cloud-native enterprise pharmacy platform, JUDI, connects every aspect of the pharmacy ecosystem in one system, empowering Capital Rx to deliver exceptional service to its commercial, Medicare, and Medicaid clients and members 24/7, 365 days a year. Together with its clients, Capital Rx is reimagining the administration of pharmacy benefits and rebuilding trust in healthcare.
To learn more about Capital Rx, visit http://www.cap-rx.com/
Contact:
Anthony Loiacono, Chief Executive Officer
855-538-8897
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.